Literature DB >> 11566919

Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet.

C Labat1, P Lacolley, M Lajemi, M de Gasparo, M E Safar, A Benetos.   

Abstract

The aim of this investigation was to evaluate the influence of a high-salt diet (HSD) on the effects of valsartan, an angiotensin II type 1 (AT(1)) receptor antagonist, on carotid arterial stiffness and structure in spontaneous hypertensive rats (SHR). Carotid arterial stiffness was studied in SHR receiving a HSD or a normal-salt diet (NSD) from the 10th to 20th week of age. Within each of the 2 groups, the animals received treatment with either placebo or valsartan (30 mg. kg(-1). d(-1)) administered on the 4th to 20th week of age. Arterial pressure, wall stress, incremental elastic modulus (Einc), medial cross-sectional area, and EIIIA fibronectin isoform were significantly increased in placebo-HSD rats compared with placebo-NSD rats with no change in the ratio of collagen to elastin. Valsartan reduced mean arterial pressure in both NSD and HSD rats but reduced pulse pressure only in NSD rats. In NSD rats, valsartan reduced Einc and medial cross-sectional area. In HSD, valsartan increased Einc and did not modify medial cross-sectional area and fibronectin. In valsartan-treated rats, the ratio of collagen to elastin was greater in HSD than in NSD rats. In conclusion, the effects of AT(1) blockade are greatly influenced by salt intake in SHR. Despite a reduction in mean arterial pressure in HSD rats, AT(1) blockade was not able to prevent the effects of a HSD on pulse pressure, carotid artery stiffness, and hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566919     DOI: 10.1161/01.hyp.38.3.439

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

Review 1.  Arterial aging--hemodynamic changes and therapeutic options.

Authors:  Michel E Safar
Journal:  Nat Rev Cardiol       Date:  2010-08       Impact factor: 32.419

Review 2.  Can antihypertensive treatment reverse large-artery stiffening?

Authors:  Michel E Safar
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 3.  Applied Healthspan engineering.

Authors:  James W Larrick; Andrew Mendelsohn
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

Review 4.  Success and failure of vaccines against renin-angiotensin system components.

Authors:  Morris J Brown
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

Review 5.  Pharmacological modulation of arterial stiffness.

Authors:  Pierre Boutouyrie; Patrick Lacolley; Marie Briet; Véronique Regnault; Alice Stanton; Stéphane Laurent; Azra Mahmud
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

6.  Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study.

Authors:  Adam Whaley-Connell; Das Purkayastha; Anthony Yadao; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-01-17       Impact factor: 2.041

7.  The effects of angiotensin-converting enzyme-inhibitory peptide LAP on the left common carotid artery remodeling in spontaneously hypertensive rats.

Authors:  F Hong; H Junling; S Yi; L Chi; Z Huan; D Yu Qing; L Lingxia; G Yang; L Ming
Journal:  Ir J Med Sci       Date:  2013-05-10       Impact factor: 1.568

8.  De-stiffening drug therapy and blood pressure control.

Authors:  Michel E Safar
Journal:  Integr Blood Press Control       Date:  2010-01-29

Review 9.  Hypertension and the elderly: more than just blood pressure control.

Authors:  Lawrence Baruch
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-05       Impact factor: 3.738

10.  Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.

Authors:  G D Radchenko; Y M Sirenko; S M Kushnir; O O Torbas; A S Dobrokhod
Journal:  Vasc Health Risk Manag       Date:  2013-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.